At the moment of the study, no diabetic participants were receiving any oral anti-diabetic agent known to affect acute pancreatitis risk or fatty liver (such as GLP-1 agonists or SGLT-2 inhibitors). This evidence concerns the gene SLC5A2 and acute pancreatitis.